These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 1316227)

  • 21. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
    Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
    Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug sensitivity of heat-resistant mouse B16 melanoma variants.
    Kroll DJ; Borgert CJ; Wiedmann TW; Rowe TC
    Radiat Res; 1990 Oct; 124(1):15-21. PubMed ID: 2236492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
    Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
    Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines.
    Brown GA; McPherson JP; Gu L; Hedley DW; Toso R; Deuchars KL; Freedman MH; Goldenberg GJ
    Cancer Res; 1995 Jan; 55(1):78-82. PubMed ID: 7805045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
    Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
    Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells.
    Lorico A; Rappa G; Sartorelli AC
    Int J Cancer; 1992 Dec; 52(6):903-9. PubMed ID: 1334054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
    Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
    Politi PM; Sinha BK
    Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression.
    Rius C; Zorrilla AR; Cabañas C; Mata F; Bernabeu C; Aller P
    Mol Pharmacol; 1991 Apr; 39(4):442-8. PubMed ID: 1850089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
    Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
    Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y; Takano H; Fojo T
    Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
    Barret JM; Calsou P; Larsen AK; Salles B
    Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.